.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,242,986

« Back to Dashboard

Claims for Patent: 9,242,986

Title:Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Abstract: A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q. ##STR00001##
Inventor(s): Kawasuji; Takashi (Osaka, JP), Nagamatsu; Daiki (Osaka, JP)
Assignee: SHIONOGI & CO., LTD. (Osaka, JP) ViiV Healthcare Company (Research Triangle Park, NC)
Application Number:14/272,823
Patent Claims: 1. A crystal form of a sodium salt of a compound of formula AA ##STR00039## having characteristic diffraction peaks at 6.4.degree..+-.0.2.degree., 9.2.degree..+-.0.2.degree., 13.8.degree..+-.0.2.degree., 19.2.degree..+-.0.2.degree. and 21.8.degree..+-.0.2.degree. degrees two-theta in an X-ray powder diffraction pattern.

2. The crystal form according to claim 1, having characteristic diffraction peaks at 6.4.degree..+-.0.2.degree., 9.2.degree..+-.0.2.degree., 13.8.degree..+-.0.2.degree., 14.6.degree..+-.0.2.degree., 15.2.degree..+-.0.2.degree., 17.6.degree..+-.0.2.degree., 19.2.degree..+-.0.2.degree., 21.8.degree..+-.0.2.degree., 24.1.degree..+-.0.2.degree. and 28.7.degree..+-.0.2.degree. degrees two-theta in an X-ray powder diffraction pattern.

3. The crystal form according to claim 1, having characteristic infrared absorption spectra at 1641 cm.sup.-1.+-.2 cm.sup.-1, 1536 cm.sup.-1.+-.2 cm.sup.-1, 1503 cm.sup.-1.+-.2 cm.sup.-1 and 1424 cm.sup.-1.+-.2 cm.sup.-1.

4. A crystal form of a sodium salt of a compound of formula AA ##STR00040## having characteristic infrared absorption spectra at 1641 cm.sup.-1.+-.2 cm.sup.-1, 1536 cm.sup.-1.+-.2 cm.sup.-1, 1503 cm.sup.-1.+-.2 cm.sup.-1 and 1424 cm.sup.-1.+-.2 cm.sup.-1.

5. The crystal form according to claim 4, having characteristic infrared absorption spectra at 1641 cm.sup.-1.+-.2 cm.sup.-1 1536 cm.sup.-1.+-.2 cm.sup.-1, 1503 cm.sup.-1.+-.2 cm.sup.-1, 1424 cm.sup.-1.+-.2 cm.sup.-1, 1282 cm.sup.-1.+-.2 cm.sup.-1, 1258 cm.sup.-1.+-.2 cm.sup.-1, 1093 cm.sup.-1.+-.2 cm.sup.-1 and 1069 cm.sup.-1.+-.2 cm.sup.-1.

6. A crystal form of a sodium salt of a compound of formula AA ##STR00041## having one or more spectra selected from the group consisting of (a) to (c): (a) X-ray powder diffraction pattern substantially as shown in FIG. 1; (b) Infrared absorption spectra substantially as shown in FIG. 2; and (c) Solid state .sup.13C-NMR spectra substantially as shown in FIG. 3.

7. A crystal form of a hydrate of a sodium salt of a compound of formula AA ##STR00042## having characteristic diffraction peaks at 8.0.degree..+-.0.2.degree., 9.3.degree..+-.0.2.degree., 11.3.degree..+-.0.2.degree., 16.0.degree..+-.0.2.degree., and 22.8.degree..+-.0.2.degree. degrees two-theta in an X-ray powder diffraction pattern.

8. The crystal form according to claim 7, having characteristic diffraction peaks at 8.0.degree..+-.0.2.degree., 9.3.degree..+-.0.2.degree., 11.3.degree..+-.0.2.degree., 15.4.degree..+-.0.2.degree., 16.0.degree..+-.0.2.degree., 18.7.degree..+-.0.2.degree., 19.1 .degree..+-.0.2.degree., 19.8.degree..+-.0.2.degree., 22.8.degree..+-.0.2.degree. and 26.8.degree..+-.0.2.degree. degrees two-theta in an X-ray powder diffraction pattern.

9. The crystal form according to claim 7, having characteristic infrared absorption spectra at 1637 cm.sup.-1.+-.2 cm.sup.-1, 1536 cm.sup.-1.+-.2 cm.sup.-1, 1501 cm.sup.-1.+-.2 cm.sup.-1 and 1422 cm-.sup.1.+-.2 cm.sup.-1.

10. A crystal form of a hydrate of a sodium salt of a compound of formula AA ##STR00043## having characteristic infrared absorption spectra at 1637 cm.sup.-1.+-.2 cm.sup.-1, 1536 cm.sup.-1.+-.2 cm.sup.-1, 1501 cm.sup.-1.+-.2 cm.sup.-1 and 1422 cm-.sup.1.+-.2 cm.sup.-1.

11. The crystal form according to claim 10, having one or more spectra selected from the group consisting of (d) and (e): (d) X-ray powder diffraction pattern substantially as shown in FIG. 4; and (e) Infrared absorption spectra substantially as shown in FIG. 5.

12. A crystal form of a hydrate of a sodium salt of a compound of formula AA ##STR00044## having one or more spectra selected from the group consisting of (d) and (e): (d) X-ray powder diffraction pattern substantially as shown in FIG. 4; and (e) Infrared absorption spectra substantially as shown in FIG. 5.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc